(Q40443948)

20 September 2017

1 reference

title

New drug binding sites in Ca2+ channels (English)

1 reference

20 September 2017

1

M. Spedding

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7610500

16 June 2024

author name string

B. Kenny

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7610500

16 June 2024

P. Chatelain

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7610500

16 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7610500

16 June 2024

publication date

1 April 1995

1 reference

full work available at URL

20 September 2017

https://api.elsevier.com/content/article/PII:S0165614700890021?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(00)89002-1

https://api.elsevier.com/content/article/PII:S0165614700890021?httpAccept=text/plain

16 June 2024

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(00)89002-1

Trends in Pharmacological Sciences

16 June 2024

published in

1 reference

20 September 2017

volume

16

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

139-142

1 reference

The naming of voltage-gated calcium channels

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Receptor sites for Ca2+ channel antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

In vitro characterization of a novel Ca2+ entry blocker: SR 33805

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Characterization of the binding of [3H]SR 33805 to the slow Ca2+ channel in rat heart sarcolemmal membrane

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Non invasive study of systemic and regional haemodynamic and cardiac effects of a new calcium antagonist, SR 33557, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Indolizinsulphones. A class of blockers with dual but discriminative effects on L-type Ca2+ channel activity and excitation-contraction coupling in skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Identification of a novel calcium antagonist binding site in rat brain by SR 33557

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Receptors for diphenylbutylpiperidine neuroleptics in brain, cardiac, and smooth muscle membranes. Relationship with receptors for 1,4-dihydropyridines and phenylalkylamines and with Ca2+ channel blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Selective antagonism of calcium channel activators by fluspirilene

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Kinetic modulation of guinea-pig cardiac L-type calcium channels by fendiline and reversal of the effects of Bay K 8644

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Different modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Pharmacological characterisation of the calcium channels coupled to the plateau phase of KCl-induced intracellular free Ca2+ elevation in chicken and rat synaptosomes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Anti-anginal arylalkylamines and sodium channels: [3H]-batrachotoxinin-A 20-alpha-benzoate and [3H]-tetracaine binding

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Prophylaxis and treatment of stroke. The state of the art in 1993.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

The effect of TYB-3823, a new antiarrhythmic drug, on sodium current in isolated cardiac cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

The effect of lifarizine (RS-87476), a novel sodium and calcium channel modulator, on ischaemic dopamine depletion in the corpus striatum of the gerbil

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Ischemic brain damage: reduction by sodium-calcium ion channel modulator RS-87476.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

U-92032, a T-type Ca2+ channel blocker and antioxidant, reduces neuronal ischemic injuries

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

A new type of Ca2+ channel blocker, NC-1100, inhibits the low- and high-threshold Ca2+ currents in the rat CNS neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

R56865 as Ca(2+)-channel blocker in Purkinje neurons of rat: comparison with flunarizine and nimodipine.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Human neocortical excitability is decreased during anoxia via sodium channel modulation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989002-1

7 January 2021

Pharmacological Reviews

1

44

363

Spedding

1992

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(00)89002-1

16 June 2024

Molecular Pharmacology

6

42

666

Kunze

1992

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(00)89002-1

16 June 2024

Molecular Pharmacology

22

45

84

Sah

1994

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(00)89002-1

Journal of Pharmacology and Experimental Therapeutics

16 June 2024

23

256

169

Takahashi

1991

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(00)89002-1

British Journal of Pharmacology

16 June 2024

27

104

156P

Fraser

1991

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(00)89002-1

Journal of Pharmacology and Experimental Therapeutics

16 June 2024

36

266

829

Lang

1993

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(00)89002-1

British Journal of Pharmacology

16 June 2024

37

107

60P

Kenny

1992

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(00)89002-1

American Journal of Physiology

16 June 2024

38

262

R712

Perez-Pinzon

1992

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(00)89002-1

16 June 2024

Molecular Pharmacology

40

45

1055

Hebert

1994

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(00)89002-1

Journal of Pharmacology and Experimental Therapeutics

16 June 2024

41

269

854

Graham

1994

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(00)89002-1

16 June 2024

Identifiers

1 reference

20 September 2017

1 reference